Giuseppe Mele

Dr. Giuseppe Mele

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2010 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
FMFortunato Morabito
Fortunato Morabito
MGMassimo Gentile
Massimo Gentile
SCStefania Ciolli
Stefania Ciolli
MPMaria T. Petrucci
Maria T. Petrucci
SGSara Galimberti
Sara Galimberti
MCMichele Cavo
Michele Cavo

7 January 2018 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
Artur JurczyszynArtur Jurczyszyn
Artur Jurczyszyn
JRJakub Radocha
Jakub Radocha
JDJulio Davila
Julio Davila
MFMark A. Fiala
Mark A. Fiala
Alessandro GozzettiAlessandro Gozzetti
Alessandro Gozzetti
JCJorge J Castillo
Jorge J Castillo

12 January 2018 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
JOJacopo Olivieri
Jacopo Olivieri
IAImmacolata Attolico
Immacolata Attolico
RNRoberta Nuccorini
Roberta Nuccorini
SPSara Pasquina Pascale
Sara Pasquina Pascale
MCMartina Chiarucci
Martina Chiarucci
AOAttilio Olivieri
Attilio Olivieri

4 January 2016 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
PDF file
Artur JurczyszynArtur Jurczyszyn
Artur Jurczyszyn
MOMagdalena Olszewska-Szopa
Magdalena Olszewska-Szopa
VHVania Hungria
Vania Hungria
ECEdvan Crusoe
Edvan Crusoe
TPTomas Pika
Tomas Pika
JCJorge J Castillo
Jorge J Castillo
Skin infiltration in multiple myeloma (skin MM) is a rare clinical problem. Only a few cases of skin involvement have been reported, primarily in single case reports. We analyzed and present the clinical outcomes, immunohistochemistry and cytogenetic features, and relevant laboratory data on 53 biopsy-proven skin MM cases. The median time from MM diagnosis to skin involvement was 2 years. There appears to be an overrepresentation of immunoglobulin class A (IgA) and light chain disease in skin MM. We found no correlation between CD56 negative MM and skin infiltration. We found that skin MM patients presented in all MM stages (i.e. ISS stages I to III), and there was no preferential cytogenetic abnormality. Patients with skin MM carry a very poor prognosis with a median overall survival (OS) of 8.5 months as time from skin involvement. Moreover, patients with IgA disease and plasmablastic morphology appear to have a worse OS.

2 July 2018 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
AJArtur Jurczyszyn
Artur Jurczyszyn
JCJorge J Castillo
Jorge J Castillo
IAIrit Avivi
Irit Avivi
JCJacek Czepiel
Jacek Czepiel
JDJulio Davila
Julio Davila
DVDavid H. Vesole
David H. Vesole
This multicenter retrospective study included 101 patients (median age 62 years) with secondary plasma cell leukemia (sPCL). The median time from initial multiple myeloma diagnosis to sPCL was 31 months. Fifty-five out of 72 patients (75%) who received any therapy were treated with immunomodulators (IMiDs) and/or proteasome inhibitors (PIs), and 14/72 (19%) underwent salvage autologous stem cell transplantation (ASCT). The overall response rate in patients who received ASCT or PI (either alone or in combination) was higher than in those who did not (93% vs. 36% and 60% vs. 30%, respectively). The median overall survival (OS) in patients who received therapy was 4.2 months (95% CI: 1.3; 8.0) with a 1-year OS of 19%. Platelet count ≤100 × 109/L at sPCL diagnosis was the only independent predictor of a poorer OS in treated patients (HR = 3.98, p = .0001). These findings suggest that patients with sPCL may benefit from salvage ASCT- and PI-based regimens.

27 February 2020 in Haematologica
Verified
Journal Article
Open access
PDF file
MGMassimo Gentile
Massimo Gentile
GSGiorgina Specchia
Giorgina Specchia
DDDaniele Derudas
Daniele Derudas
MGMonica Galli
Monica Galli
CBCirino Botta
Cirino Botta
FMFortunato Morabito
Fortunato Morabito